Sequentify Appoints Dr. Ravi Majeti as Scientific Advisor

"Sequentify's approach to scalable, simplified sequencing is exactly what the field of genomic testing needs," said
About Sequentify:
Founded in 2021 as a Weizmann Institute spinoff, Sequentify enables decentralized, population-wide genomic sequencing by providing laboratories with the easiest and quickest solutions available. Their technology facilitates the scaling-up of genomic testing by directly addressing the current pain points in the industry, through sample-prep and software solutions. The company offers panels for oncology and screening applications, and infectious diseases, with a focus on the clinical market. Sequentify is based in
Logo: https://mma.prnewswire.com/media/2269535/SEQUENTIFY_Logo.jpg
Media Contact:
[email protected]
View original content:https://www.prnewswire.com/news-releases/sequentify-appoints-dr-ravi-majeti-as-scientific-advisor-302518449.html
SOURCE Sequentify ltd.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- In HelloNation, Water Treatment Expert Will Breault Details the Differences Between Water Softeners & Reverse Osmosis
- New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients
- NEOS Investments Announces September 2026 ETF Suite Distributions
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share